GENOMIC HEALTH, INC. (NASDAQ:GHDX) Files An 8-K Results of Operations and Financial Condition

GENOMIC HEALTH, INC. (NASDAQ:GHDX) Files An 8-K Results of Operations and Financial Condition
Item 2.02Results of Operations and Financial Condition.

Story continues below

On August 1, 2017, Genomic Health, Inc. issued a press release announcing financial results for its second fiscal quarter ended June 30, 2017.The full text of the press release is furnished as Exhibit99.1.

Item 9.01Financial Statements and Exhibits.

(d)Exhibits

99.1Press release issued by Genomic Health, Inc. dated August 1, 2017.


GENOMIC HEALTH INC Exhibit
EX-99.1 2 ex-99d1.htm EX-99.1 ghdx_Ex99-1 Exhibit 99.1   Investor and Media Contact: Emily Faucette Genomic Health 650-569-2824 [email protected]     Genomic Health Announces Second Quarter 2017 Financial Results and Reports Recent Business Progress Delivered 9 Percent Increase in Test Volume; 4 Percent Increase in Revenue Continued to Generate Strong Test Demand with 5 Percent Increase in U.S. Invasive Breast Cancer,…
To view the full exhibit click here

About GENOMIC HEALTH, INC. (NASDAQ:GHDX)

Genomic Health, Inc. is a healthcare company, which provides genomic-based diagnostic tests for the treatment of early stage cancer. The Company offers its Oncotype DX tests as a clinical laboratory service, where it analyzes the expression levels of genes in tumor tissue samples and provides physicians with a quantitative gene expression profile expressed as a single quantitative score, which it calls a Recurrence Score for invasive breast cancer and colon cancer, a DCIS Score for ductal carcinoma in situ (DCIS) and a Genomic Prostate Score for prostate cancer. Its Oncotype DX tests utilizes quantitative genomic analysis known as reverse transcription polymerase chain reaction, in standard tumor pathology specimens to provide tumor-specific information, or the oncotype of a tumor. It offers its services and products, including Oncotype DX Breast Cancer Test, Oncotype DX Colon Cancer Test and Oncotype DX Prostate Cancer Test through its Oncotype IQ Genomic Intelligence Platform.

An ad to help with our costs